Is Zolbetuximab-Vyloy covered by health insurance?

Zolbetuximab (Zolbetuximab), trade name Vyloy, is a new type of targeted antibody drug specifically used to treat patients with HER2-negative gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, especially those who are Claudin 18.2 (CLDN18.2) positive. This drug helps eliminate cancer cells by targeting the Claudin 18.2 protein and has shown excellent efficacy in clinical studies. However, while many patients are concerned about the effects of drug treatment, they are also concerned about the cost of treatment, especially whether the drug is included in medical insurance and whether it can reduce the financial burden.

At present, zotuximab has not been officially included in medical insurance in the Chinese market. This means that patients usually have to bear higher drug costs when using the drug. Because this drug is an innovative drug, its treatment cost is relatively high, especially when it has not yet been widely popularized and generic drugs have not yet been launched. The price of the drug may put greater economic pressure on patients' treatment options.

Although zotuximab has not yet entered medical insurance, its clinical application potential and efficacy have made the drug's status in the treatment of gastric cancer and other tumors continue to increase. As the clinical use of this drug gradually increases at home and abroad, it may be included in medical insurance over time in the future to reduce the financial burden on patients.

At present, domestic medical institutions are still in a stage of gradual promotion of the use of zotuximab. Patients usually purchase drugs through hospital pharmacies, and drug prices vary between hospitals, regions and drug supply channels. For patients with limited financial resources, some medical institutions may provide pharmaceutical assistance or support programs to help patients obtain necessary treatment support.

Reference: https://go.drugbank.com/drugs/DB15118